Patents Examined by John S Kenyon
  • Patent number: 10927090
    Abstract: A method suitable for large-scale production of buagafuran active pharmaceutical ingredient. A buagafuran active pharmaceutical ingredient (API) with a high purity prepared by the method includes an active ingredient of buagafuran, an impurity A, and an impurity B. In the buagafuran API, a content of the active ingredient of buagafuran is higher than 97.5%, and a total content of the impurity A and the impurity B is less than 0.04%. The buagafuran API can be applied to new drug development processes such as clinical research, pharmaceutical research and quality control research.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: February 23, 2021
    Assignee: BEIJING UNION PHARMACEUTICAL FACTORY
    Inventor: Bo Song
  • Patent number: 10927101
    Abstract: The present invention relates to novel pyridine nucleoside compounds, Neopetroside A (NPS A) and Neopetroside B (NPS B) obtained by fractionating an extract of Neopetrosia sp. which is a marine sponge, with ethanol, into n-butanol (n-BuOH). When the NPS A was treated with myocardial cells, it activates oxidative phosphorylation, basal and mitochondrial respiration induced by ATP and ATP synthesis, and stimulates the glycolysis activity and when the NPS A was treated with an ischemic reperfusion injury model, the left ventricular pressure injured by ischemic reperfusion was recovered and the size of myocardial injury site was significantly reduced and as a result, can be provided as the pharmaceutical composition for preventing or treating ischemic heart disease or the health functional food for preventing or improving the same.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: February 23, 2021
    Assignee: INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Jin Han, Seung Hun Jeong, In-Sung Song, Hyoung Kyu Kim, Nari Kim, Larisa K. Shubina, Tatyana N. Makarieva, Valentin A. Stonik, Dmitry V. Yashunsky, Nikolay E. Nifantiev
  • Patent number: 10930855
    Abstract: An object is to provide a light-emitting element with a favorable lifetime.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: February 23, 2021
    Assignee: Semiconductor Energy Laboratory Co., Ltd.
    Inventors: Yusuke Takita, Satoshi Seo, Tsunenori Suzuki, Harue Osaka
  • Patent number: 10925874
    Abstract: Substituted pyrazolopyrimidines and dihydropyrazolopyrimidines and related compounds, their methods of manufacture, compositions containing these compounds, and methods of use of these compounds in treating lysosomal storage disorders such as Gaucher disease are described herein. The compounds are of general Formula (I) in which variables R1-R7 and X are described in the application.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: February 23, 2021
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Juan Jose Marugan, Noel Southall, Ehud Goldin, Wei Zheng, Samarjit Patnaik, Ellen Sidransky, Omid Motabar, Wendy Westbroek
  • Patent number: 10919921
    Abstract: The present invention relates to chiral compounds with two optically active phosphorus atoms, chiral transition metal catalysts which comprise these compounds as ligands, a process for preparing the P-chiral compounds and processes for asymmetric synthesis using the chiral transition metal catalysts. The present invention specifically relates to a process for preparing an optically active carbonyl compound by asymmetric hydrogenation of a prochiral ?,?-unsaturated carbonyl compound with hydrogen in the presence of an optically active transition metal catalyst according to the invention. Yet more specifically, the present invention relates to a process for the asymmetric hydrogenation of citral, and also a process for preparing optically active menthol.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: February 16, 2021
    Inventors: Armin Boerner, Jens Holz, Katharina Rumpel
  • Patent number: 10919908
    Abstract: The disclosure relates to a thienopyrimidinone derivative, or a pharmaceutically acceptable prodrug, salt, and solvate thereof. The derivative has the formula (I), where R represents hydrogen (H) or deuterium (D); R1 and R2 independently, at each occurrence, represent H, D, F, Cl, I, cyano group (CN), or N3, and when R represents H, R1 and R2 do not synchronously represent H; R3, R4 and R5 independently, at each occurrence, represent an alkyl group, a cycloalkyl group, a heterocyclic group, an aromatic ring group, or a heteroaryl ring group, which are substituted or unsubstituted.
    Type: Grant
    Filed: July 5, 2019
    Date of Patent: February 16, 2021
    Assignee: HENAN GENUINE BIOTECH CO., LTD.
    Inventors: Junbiao Chang, Jinfa Du
  • Patent number: 10906883
    Abstract: Disclosed are methods for preparing a salt of urolithin A and, in turn, urolithin A. The methods are advantageous for the large-scale preparation of urolithin A or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: February 2, 2021
    Assignee: Amazentis SA
    Inventors: Wolfgang Skranc, George Yiannikouros, Alexander Trofimov, Zhixing Shan, Christopher Goss
  • Patent number: 10905118
    Abstract: The inventive subject matter relates to compounds of Formula I and Formula II, compositions thereof, and processes for making such compounds as presently claimed and further described herein. The inventive compounds and compositions have antimicrobial properties and are useful as environmental disinfectants, topical cleansers such as topical personal care compositions, sanitizers, preservatives, in water treatment, as permanent or erodible coatings for medical devices and appliances, and in therapeutics.
    Type: Grant
    Filed: October 24, 2015
    Date of Patent: February 2, 2021
    Assignee: JAMES MADISON INNOVATIONS, INC.
    Inventors: Kevin L. Caran, Kyle Seifert
  • Patent number: 10899726
    Abstract: A process for the production of aromatic primary amines, by reacting an aromatic dialdehyde with hydrogen and ammonia or an ammonia-liberating compound, in the presence of a hydrogenation catalyst and an amine, wherein the molar ratio of the amine to the aromatic dialdehyde is no less than 1:4 at the start of the reaction.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: January 26, 2021
    Assignee: RHODIA OPERATIONS
    Inventors: Peng Li, Floryan Decampo
  • Patent number: 10875836
    Abstract: Described herein are compounds of the formula (I)-(III) (or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof), as well as methods of making and using compounds of the formula (I)-(III) to, among other things, treat various forms of cancer.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: December 29, 2020
    Assignee: Purdue Research Foundation
    Inventors: Arun K. Ghosh, Luke A. Kassekert
  • Patent number: 10875874
    Abstract: Disclosed are a compound as shown in formula I or formula II or a pharmaceutically acceptable salt thereof, wherein R1 is selected from pyrazinyl or substituted pyrazinyl; and R2 is selected from pyrazinyl or substituted pyrazinyl, phenyl or substituted phenyl, alkyl or substituted alkyl.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: December 29, 2020
    Assignee: Chengdu Baiyu Ginkgolide Pharmaceuticals Co. Ltd.
    Inventors: Daxiong Li, Huiqin Li, Hong Ke, Xiaobo Fan, Yi Sun
  • Patent number: 10869861
    Abstract: This application relates to methods of treating attention deficit hyperactivity disorder (ADHD), 22q deletion and/or duplication syndrome, and co-morbidities with a nonselective activator of metabotropic glutamate receptors, such as fasoracetam, for example, in subjects having a genetic alteration in at least one metabotropic glutamate receptor (mGluR) network gene.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: December 22, 2020
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Hakon Hakonarson, Charlly Kao
  • Patent number: 10870647
    Abstract: The present invention relates to a novel imidazopyridine derivative, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer. The novel imidazopyridine derivative according to the present invention, a stereoisomer thereof and a pharmaceutically acceptable salt thereof can effectively inhibit cancer-related kinases, are excellent in inhibiting proliferation of cancer cells in a cancer cell line, and effectively inhibit proliferation of cancer cells (cancer cell apoptosis) in a cancer cell heterograft model, and thus can be useful as a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: December 22, 2020
    Assignee: DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION
    Inventors: Hwan Geun Choi, Jung Beom Son, Shinae Kim, Seungyeon Lee, Eunhwa Ko, Joongheui Cho, Seock Yong Kang, So Young Kim, Jin-Hee Park, Yi Kyung Ko, Hee Yoon Ryu, Nam Doo Kim, Hyunkyoung Kim, Younho Lee, Sun-Hwa Lee, Dayea Kim, Sun Joo Lee, Seongho Hong, Sang Hyun Min, Sungwoo Lee, Dong Kyu Choi, Jae Hyun Bae, Eunmi Hong, Tae-Ho Jang, Jaeyoung Song, Sangbum Kim, Suk Kyoon Yoon
  • Patent number: 10864196
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: December 15, 2020
    Assignees: Calico Life Sciences, LLC, AbbVie Inc.
    Inventors: Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei I. Zhang, Yunsong Tong, Charles W. Hutchins, Seungwon Chung, Michael J. Dart
  • Patent number: 10865216
    Abstract: Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. In addition, species of tricyclic gyrase inhibitors compounds are also disclosed herein. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.
    Type: Grant
    Filed: September 11, 2013
    Date of Patent: December 15, 2020
    Assignees: MERCK SHARP & DOHME CORP., LAWRENCE LIVERMORE NATIONAL SECURITY, LLC
    Inventors: Daniel Bensen, Allen Borchardt, Zhiyong Chen, John M. Finn, Thanh To Lam, Suk Joong Lee, Xiaoming Li, Leslie William Tari, Min Teng, Michael Trzoss, Junhu Zhang, Michael E. Jung, Felice C. Lightstone, Sergio E. Wong, Toan B. Nguyen
  • Patent number: 10865191
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: A is CR1 or N; B is CR3 or N; D is CR4 or N; L1 is —(CR7R7)m—; L2 is —(CR7R7)n—; and X, Z, R1, R2, R3, R4, R5, and R6 are define herein. Also disclosed are methods of using such compounds as modulators of TNF?, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: December 15, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Hai-Yun Xiao, T. G. Murali Dhar, Ning Li, Jingwu Duan, Bin Jiang, Zhonghui Lu, Khehyong Ngu, William J. Pitts, Joseph A. Tino
  • Patent number: 10858325
    Abstract: Disclosed embodiments relate to improved methods for the synthesis of activated fumarate intermediates and their use in chemical synthesis. Disclosed embodiments describe the synthesis of activated fumarate esters including those derived from activating groups including: 4-nitrophenyl, diphenylphophoryl azide, pivaloyl chloride, chlorosulfonyl isocyanate, p-nitrophenol, MEF, trifluoroacetyl and chlorine, for example, ethyl fumaroyl chloride and the subsequent use of the activated ester in situ. Further embodiments describe the improved synthesis of substituted aminoalkyl-diketopiperazines from unisolated and unpurified intermediates allowing for improved yields and reactor throughput.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: December 8, 2020
    Assignee: MANNKIND, CORP.
    Inventors: Kelly Sullivan Kraft, John J. Freeman, Paul Serwinski, Vincent Pavia, Otto Phanstiel, Navneet Kaur
  • Patent number: 10858388
    Abstract: The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11?,17?)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one for the treatment and/or prophylaxis of Uterine Fibroids (myomas, uterine leiomyoma) that is administered to a patient diagnosed with Uterine Fibroids following a specific regimen. Additionally, the invention is directed to a method for treating Uterine Fibroids (myomas, uterine leiomyoma) and/or for reducing Uterine Fibroids (myomas, uterine leiomyoma) size and symptoms related to Uterine Fibroids following a specific regimen as well as treatment of Heavy Menstrual Bleeding (HMB).
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: December 8, 2020
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Christian Seitz, Rudolf Knauthe, Susan Zeun
  • Patent number: 10858329
    Abstract: The present invention provides novel solutions to the problem of recycling carbonylation catalysts in epoxide carbonylation processes. The inventive methods are characterized in that the catalyst is recovered in a form other than as active catalyst. In some embodiments, catalyst components are removed selectively from the carbonylation product stream in two or more processing steps. One or more of these separated catalyst components are then utilized to regenerate active catalyst which is utilized during another time interval to feed a continuous carbonylation reactor.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: December 8, 2020
    Assignee: Novomer, Inc.
    Inventor: Sadesh H. Sookraj
  • Patent number: 10858307
    Abstract: Provided herein are compositions and methods of treating liver cancer by novel anticancer agents.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: December 8, 2020
    Assignee: Golden Biotechnology Corporation
    Inventors: Sheng-Yung Liu, Chih-Ming Chen